Update on Regeneron’s Supplemental BLA for EYLEA HD
By EsqSocial Corporation 30/04/25
On April 18, 2025, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the supplemental Biologics License Application for EYLEA HD (aflibercept). ...
By: Goodwin